Flex Innovation Group

Editas Medicine, headquartered in Cambridge, Massachusetts, is a pioneering biotechnology company focused on leveraging CRISPR gene editing technology to develop transformative therapies for patients. The company went public on February 3, 2016, and is traded on the NASDAQ Global Market under the ticker symbol EDIT. With a commitment to innovation, Editas Medicine aims to advance genetic medicine through its robust research pipeline and dedicated team. The company is supported by a strong network of financial and legal partnerships, ensuring its ongoing growth and adherence to regulatory standards. Generated from the website

Rhythm Pharmaceuticals is a Boston-based company dedicated to transforming the lives of patients and their families affected by hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. They are focused on developing precision medicines that address the root cause of these conditions by targeting the MC4R pathway, which regulates weight and hunger. Through their translational research and clinical development programs, Rhythm Pharmaceuticals aims to provide innovative therapies for rare genetic diseases of obesity. With a strong emphasis on patient care, Rhythm Pharmaceuticals is committed to advancing the understanding and treatment of hyperphagia and severe obesity. They leverage the largest known DNA database focused on obesity to drive their research efforts and develop therapies for rare obesities linked to variants in specific genes with relevance to the MC4R pathway. By pioneering new approaches and therapies, Rhythm Pharmaceuticals is at the forefront of transforming the care of individuals living with rare genetic diseases of obesity.Generated from the website

OPKO Health Inc. is a fully-integrated healthcare company dedicated to improving patients' lives through next-generation solutions for serious diseases. With a focus on innovative therapies such as NGENLA and RAYALDEE, OPKO collaborates with leading pharmaceutical partners to advance proven technologies in established global markets. In addition to its therapeutic advancements, OPKO boasts one of the largest full-service clinical reference laboratories in the U.S., serving approximately 11 million patients annually. The company's robust research efforts aim to develop multispecific therapies addressing complex conditions, leveraging partnerships with renowned organizations to ensure the broadest impact of its innovations. Generated from the website